Literature DB >> 11944896

Identification of LPS-binding peptide fragment of MD-2, a toll-receptor accessory protein.

Mateja Mancek1, Primoz Pristovsek, Roman Jerala.   

Abstract

Members of the toll-like receptor family are crucial in recognition of microbial pathogens as part of innate immune response. MD-2, an accessory protein to TLR4, present on the extracellular side of the membrane is needed to initiate the signal transduction. We have identified a 15 amino acid region of human MD-2 that contains several features of other lipopolysaccharide (LPS) binding proteins and peptides. In vitro LPS neutralization by this peptide was observed and confirmed by 2D transferred NOESY NMR experiments. NMR experiments have also shown binding of the MD-2 peptide to lipoteichoic acid (LTA) but not to peptidoglycan. Furthermore this peptide inhibited growth of gram-negative and to a lower extent of some gram-positive bacteria. Our results indicate that this region of MD-2 might be responsible for binding of LPS and confirms the role of MD-2 as an accessory protein in LPS signaling bestowing the Toll receptors their specificity. (c)2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11944896     DOI: 10.1006/bbrc.2002.6748

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Identification of a novel human MD-2 splice variant that negatively regulates Lipopolysaccharide-induced TLR4 signaling.

Authors:  Pearl Gray; Kathrin S Michelsen; Cherilyn M Sirois; Emily Lowe; Kenichi Shimada; Timothy R Crother; Shuang Chen; Constantinos Brikos; Yonca Bulut; Eicke Latz; David Underhill; Moshe Arditi
Journal:  J Immunol       Date:  2010-04-30       Impact factor: 5.422

2.  An MD2-derived peptide promotes LPS aggregation, facilitates its internalization in THP-1 cells, and inhibits LPS-induced pro-inflammatory responses.

Authors:  Anshika Tandon; Munesh Kumar Harioudh; Nayab Ishrat; Amit Kumar Tripathi; Saurabh Srivastava; Jimut Kanti Ghosh
Journal:  Cell Mol Life Sci       Date:  2018-01-08       Impact factor: 9.261

3.  Apolipoprotein CI enhances the biological response to LPS via the CD14/TLR4 pathway by LPS-binding elements in both its N- and C-terminal helix.

Authors:  Jimmy F P Berbée; Claudia P Coomans; Marit Westerterp; Johannes A Romijn; Louis M Havekes; Patrick C N Rensen
Journal:  J Lipid Res       Date:  2010-03-24       Impact factor: 5.922

4.  Comparison of lipopolysaccharide-binding functions of CD14 and MD-2.

Authors:  Jun Koraha; Naoko Tsuneyoshi; Masao Kimoto; Jean-Francois Gauchat; Hiroshi Nakatake; Kenji Fukudome
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

Review 5.  C1 inhibitor: biologic activities that are independent of protease inhibition.

Authors:  Alvin E Davis; Shenghe Cai; Dongxu Liu
Journal:  Immunobiology       Date:  2006-12-11       Impact factor: 3.144

6.  The role of disulfide bonds in the assembly and function of MD-2.

Authors:  Gregory E D Mullen; Margaret N Kennedy; Alberto Visintin; Alessandra Mazzoni; Cynthia A Leifer; David R Davies; David M Segal
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

Review 7.  Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues.

Authors:  Aileen F B White; Alexei V Demchenko
Journal:  Adv Carbohydr Chem Biochem       Date:  2014       Impact factor: 12.200

8.  MD-2 is necessary for the toll-like receptor 4 protein to undergo glycosylation essential for its translocation to the cell surface.

Authors:  Takahiro Ohnishi; Masashi Muroi; Ken-Ichi Tanamoto
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

9.  Signatures of positive selection in LY96 gene in vertebrates.

Authors:  Tonghai Dou; Maobin Fu; Yixia Wang; Yang Zhao; Zhengshi Wang; Zhengqian Bian; Yan Zhou
Journal:  J Biosci       Date:  2013-12       Impact factor: 1.826

10.  Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis.

Authors:  Arunan S Vamadevan; Masayuki Fukata; Elizabeth T Arnold; Lisa S Thomas; David Hsu; Maria T Abreu
Journal:  Innate Immun       Date:  2009-08-26       Impact factor: 2.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.